Corbus Pharmaceuticals Presents Phase 1B CANYON-1 Clinical Trial Data For CRB-913 At Obesityweek® 2026
| CRB-913 | ||||
| Cohort | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| LS mean weight loss from baseline at week 12, %1 | 0.0% | 2.8% | 3.3% | 5.0% |
| LS mean weight loss at week 12, % (placebo-adjusted)1 | NA | 2.8% | 3.3% | 5.0% |
| p-value vs. placebo | NA | <0.0001 | <0.0001 | <0.0001 |
| Change in waist circumference from baseline, cm | -0.84 | -3.03 | -3.04 | -3.94 |
| p-value | 0.21 | <0.0001 | <0.0001 | <0.0001 |
| BMI percent change from baseline | -0.06 | -2.81 | -3.34 | -4.99 |
| p-value | 0.89 | <0.0001 | <0.0001 | <0.0001 |
1 Efficacy estimand. The LS means and p-values were derived using a mixed model for repeated measures (MMRM), with percent change from baseline as the dependent variable; sex, treatment group, visit, and the treatment group-by-visit interaction as categorical fixed effects; and baseline weight as a covariate. An unstructured covariance matrix was used.
All participants who completed the study and received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5.0% from baseline. Similarly, 6.7% of the participants in that cohort lost more than 7.5% of their weight from baseline. The highest recorded weight loss for this cohort was 13.4% from baseline. Participants treated with CRB-913 also experienced dose-dependent reductions in waist circumference and body mass index during the study.
Safety
CRB-913 was safe and well tolerated. The treatment discontinuation rate due to AEs across all study cohorts was low at 8.3%, which is in line with published GLP-1 data.
| CRB-913 | |||||
| Safety measure | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) | Total (N = 254) |
| Any TEAE, n (%) | 28 (42.4) | 39 (60.0) | 45 (73.8) | 45 (72.6) | 157 (61.8) |
| Severe TEAE | 0 (0.0) | 3 (4.6) | 2 (3.3) | 1 (1.6) | 6 (2.4) |
| Severe psychiatric TEAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Severe gastrointestinal TEAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Serious TEAE | 0 (0.0) | 2 (3.1) | 1 (1.6) | 1 (1.6) | 4 (1.6) |
| Any TRAE, n (%) | 14 (21.2) | 27 (41.5) | 34 (55.7) | 33 (53.2) | 108 (42.5) |
| Severe TRAE | 0 (0.0) | 0 (0.0) | 1 (1.6) | 0 (0.0) | 1 (0.4) |
| Serious TRAE | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Treatment discontinuation for any reason, n (%) | 12 (18.2) | 10 (15.4) | 16 (26.2) | 16 (25.8) | 54 (21.3) |
| Treatment discontinuation due to an AE, n (%) | 3 (4.5) | 2 (3.1) | 8 (13.1) | 8 (12.9) | 21 (8.3) |
Psychiatric Adverse Events
Treatment-emergent psychiatric AEs were infrequent and mostly mild, and all resolved. No serious or severe psychiatric AEs were reported.
| CRB-913 | ||||
| Adverse event, n (%) | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| Suicidality | 0 | 0 | 0 | 0 |
| Depressive symptoms | 0 | 0 | 0 | 1 (1.6%) (moderate) |
| Anxiety | 3 (4.5%) | 2 (3.1%) | 5 (8.2%) | 3 (4.8%) |
Fifty percent of the psychiatric AEs occurred within the first 28 days, a pattern similar to that seen with GLP-1 analogs. No cases of suicidal ideation or serious or severe depression were observed. Psychiatric AEs did not appear to be dose-related; rates of depression and anxiety were in line with those reported in published GLP-1 studies. Only one of the 188 participants receiving CRB-913 reported transient, moderate depressive symptoms, a rate that is in line with published GLP-1 data. A total of 15 participants (8%) on CRB-913 reported mild irritability that was transient, resolved spontaneously, and did not affect their daily function. All 15 participants experienced weight loss, and 12 participants had concomitant unrelated AEs.
Gastrointestinal Adverse Events
Treatment-emergent gastrointestinal AEs were all mild or moderate, with no serious or severe events.
| CRB-913 | ||||
| Adverse event, n (%) | Placebo (n = 66) | 20 mg (n = 65) | 40 mg (n = 61) | 60 mg (n = 62) |
| Vomiting | 0 | 3 (4.6%) | 5 (8.2%) | 1 (1.6%) |
| Nausea | 3 (4.5%) | 10 (15.4%) | 16 (26.2%) | 14 (22.6%) |
| Constipation | 2 (3.0%) | 3 (4.6%) | 1 (1.6%) | 3 (4.8%) |
| Diarrhea | 2 (3.0%) | 14 (21.5%) | 16 (26.2%) | 14 (22.6%) |
Vomiting, nausea, and constipation occurred at lower rates and were less severe than those reported in published studies of oral GLP-1s. Treatment discontinuations due to gastrointestinal AEs occurred in only three participants (two on CRB-913 and one on placebo).
Next Steps
Corbus plans to engage with the FDA to discuss the data and the development plans for CRB-913. The Company is also evaluating the potential for CRB-913 in combination with GLP-1 therapies.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes SUTA-E (sutantatug envedotin), a next-generation antibody-drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered, highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn, and Facebook.
Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the potential benefits and development of CRB-913, future clinical studies and regulatory discussions, potential combination therapies, development timing and funding. They reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual outcomes to differ materially. These include the possibility that early clinical findings will not be reproduced in larger or longer studies; additional safety findings or changes following further analysis; delays in clinical or regulatory activities; and the availability and terms of financing or partnering arrangements. Further risks are described under the heading“Risk Factors” in Corbus most recent Annual Report on Form-10-K and subsequent Quarterly Reports on Form10-Q filed with the Securities and Exchange Commission. Forward-looking statements apply only as of the date of this release. Corbus does not undertake to update them except as required by law.
Investor Contacts
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
...
Dan Ferry
Managing Director
LifeSci Advisors, LLC
...
Media Contact
Liz Melone
Founder and Principal
Melone Communications, LLC
...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment